Gainers
- Owlet OWLT supply climbed 32.0% to $0.45 throughout Friday’s after-market session. Owlet’s trading quantity struck 1.5 million shares by close, making up 521.2% of its typical quantity over the last 100 days. The firm’s market cap stands at $51.6 million.
- scPharmaceuticals SCPH supply climbed 9.39% to $10.36. The firm’s market cap stands at $352.8 million.
- NeuBase Therapies NBSE supply relocated up-wards by 7.01% to $0.28. The firm’s market cap stands at $9.4 million. According to journalism launch, Q1 profits appeared 3 days earlier.
- TransCode Therapies RNAZ shares climbed 6.12% to $0.56. This protection traded at a quantity of 1.0 million shares come close, comprising 26.3% of its typical quantity over the last 100 days. The marketplace worth of their superior shares goes to $7.2 million.
- Benitec Biopharma BNTC shares raised by 5.49% to $0.22. The firm’s market cap stands at $6.2 million. According to journalism launch, Q2 profits appeared 4 days earlier.
- Vaccinex VCNX supply relocated up-wards by 5.12% to $0.53. The marketplace worth of their superior shares goes to $26.6 million.
Losers
- OKYO Pharma OKYO supply decreased by 10.4% to $3.35 throughout Friday’s after-market session. At the close, OKYO Pharma’s trading quantity got to 168.7 K shares. This is 2444.5% of its typical quantity over the last 100 days. The firm’s market cap stands at $73.0 million.
- Evolus EOLS shares dropped 9.49% to $8.4. The marketplace worth of their superior shares goes to $472.4 million.
- Tenon Medical TNON supply decreased by 7.05% to $2.11. The firm’s market cap stands at $23.7 million.
- Baudax Biography BXRX supply dropped 5.56% to $2.72. The firm’s market cap stands at $1.5 million.
- Hims & & Hers Health And Wellness HIMS supply lowered by 5.35% to $9.12. The marketplace worth of their superior shares goes to $1.8 billion.
- Aptinyx APTX shares lowered by 5.14% to $0.55. The marketplace worth of their superior shares goes to $37.2 million.
See Likewise: www.benzinga.com/money/best-healthcare-stocks/
This post was produced by Benzinga’s computerized material engine as well as assessed by an editor.
© 2023 Benzinga.com. Benzinga does not give financial investment guidance. All legal rights booked.